Financial Data and Key Metrics Changes - The company is unable to provide detailed financial results due to the deconsolidation of Invizyne's financial statements, which has delayed the filing of the 10-K report [6][14][25] - As of December 31, the combination of cash and securities was 64 million, totaling approximately 6.30, with approximately 9.9 million shares outstanding, resulting in a market value of 30 million [58][59] Business Line Data and Key Metrics Changes - The company has successfully launched eXoZymes, marking a significant achievement despite challenging market conditions for small IPOs [14][15] - The shareholder count has increased by 12%, reaching approximately 1,800 shareholders [15] - The onboarding of investors through MDB Direct has begun, with over 500 accounts established by year-end [16] Market Data and Key Metrics Changes - There is a growing demand for microcap financing, with investors seeking liquid alternatives, positioning the company as a top curator of public venture opportunities [32] - The traditional venture capital and private equity markets are facing challenges, leading to increased interest from companies looking to go public [30][31] Company Strategy and Development Direction - The primary strategic priority for the company is to expand its investor community, focusing on partnerships with RIAs and angel groups [35][41] - The company aims to present one to two new Big Idea investment opportunities in the next quarter, indicating a robust pipeline of potential investments [52][53] - The company is evolving from a model of episodic deal-making to creating a consistent public venture asset class portfolio [34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the increasing number of opportunities being presented, both from community members and through proactive curation [26][27] - The regulatory environment is perceived as improving, which may facilitate new offerings, although there are concerns regarding the FDA's approval timelines [87][88] - The company is focused on maintaining operational efficiencies while managing cash expenditures, with hopes of reducing operational costs over the next 12 months [62] Other Important Information - The company has licensed new assets from Mayo Clinic and is developing this opportunity, although no specific updates were provided [49][50] - The company continues to work with HeartBeam, which is developing groundbreaking technology for self-administered ECGs, with significant market potential [44] Q&A Session Summary Question: Does Lou Basenese still work for the organization? - Lou Basenese has left the company but remains a friend and supporter, focusing on his media presence [65][66] Question: What does the deconsolidation mean for MDB stockholders and eXoZymes' investors? - The deconsolidation will clarify the financials of MDB, separating its performance from eXoZymes, making it easier for investors to understand [70][71] Question: How many Big Idea companies are expected to be established in 2025? - The company anticipates presenting three to four new Big Ideas in 2025, with some companies already in advanced discussions for potential IPOs [80][81] Question: How do you see the regulatory winds changing? - The regulatory environment is expected to improve, facilitating new offerings, although there are uncertainties regarding FDA timelines [87][88] Question: When do you expect to make any type of dividend? - The company aims to wait for a solid footing under eXoZymes before considering any distributions to avoid disrupting the market [92][93] Question: How should shareholders think about the investment in cash and resources relative to value creation? - The company intends to maintain a modest amount of cash for new opportunities while leveraging existing investments to create value [99][100]
MDB Capital (MDBH) - 2024 Q4 - Earnings Call Transcript